Chiva CEO: Ligand deal raises bar for Chinese pharma industry
This article was originally published in Scrip
Executive Summary
Ligand Pharmaceuticals licensed the rights to its selective estrogen receptor modulator (SERM) Fablyn (lasofoxifene) to Chiva Pharmaceuticals for $4 million, which will be paid over the next eight months, plus undisclosed milestones and royalties on worldwide sales.